Browse by Poster Presenter

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

F
Fabbroni, Chiara

Fondazione IRCCS Istituto Nazionale dei Tumori MILANO
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Chiara Fabbroni
Favorite
Fabbroni, Chiara

Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Chiara Fabbroni
Favorite
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Chiara Fabbroni
Favorite
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Chiara Fabbroni
Favorite
(P 420) CELLULARITY DEGREES IN PRIMARY MYXOID LIPOSARCOMA: ASSOCIATION WITH TUMOR IMMUNE INFILTRATE AND PATIENT OUTCOMES
Chiara Fabbroni
Favorite
Facchin, Caterina

Research Institute McGill University Health Center
(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Caterina Facchin
Favorite
Facklam, Amanda

Pyxis Oncology
(P 339) SARCOMAS EXPRESS EXTRA DOMAIN B OF FIBRONECTIN AND PRECLINICAL PATIENT-DERIVED XENOGRAFT MODELS OF SEVERAL SARCOMA SUBTYPES ARE SENSITIVE TO THE STROMA TARGETING ANTIBODY DRUG CONJUGATE PYX-201
Amanda Facklam
Favorite
Fagan-Kellogg, Sarah

Duke University Hospital
(P 54) CHONDROBLASTIC OSTEOSARCOMA IS A RISK FACTOR FOR LOCAL RECURRENCE IN PATIENTS WITH SKELETAL OSTEOSARCOMA
Sarah Fagan-Kellogg
Favorite
Fagioli, Franca

University of Turin
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Franca Fagioli
Favorite
Fairweather, Mark

Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Mark Fairweather
Favorite
Falcon Gonzalez, Alejandro

Hospital Universitario Virgen del Rocío Sevilla and Instituto de BioMedicina de Sevilla
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Alejandro Falcon Gonzalez
Favorite
Fang, Mei-Yu

Department of Head and Neck and Rare Tumors Internal Medicine, ZheJiang Cancer Hospital, Hangzhou, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Mei-Yu Fang
Favorite
Fanta, Paul

University of California, San Diego
(P 165) COMPLETE PERITONEAL CYTOREDUCTIVE SURGERY IN HIGHLY SELECTED PATIENTS WITH AGGRESSIVE METASTATIC SDH-DEFICIENT GIST CAN PROLONG EVENT-FREE SURVIVAL
Paul Fanta
Favorite
(P 175) KIT AND DOG-1 EXPRESSING GASTROINTESTINAL STROMAL TUMORS HARBORING ETV6-NTRK3 FUSIONS DO EXIST, CASE OF NEAR COMPLETE PATHOLOGIC RESPONSE FOLLOWING LAROTRECTINIB AND REVIEW OF THE LITERATURE
Paul Fanta
Favorite
Fan, Timothy

University of Illinois Urbana-Champaign
(P 79) NOVEL THERAPEUTIC POTENTIAL THROUGH HYPERACTIVATION OF THE ANTICIPATORY UNFOLDED PROTEIN RESPONSE PATHWAY IN BONE CANCER TREATMENT
Timothy Fan
Favorite
(P 419) BONE MECHANICS INFLUENCE CANCER STEM CELL FORMATION IN OSTEOSARCOMA
Timothy Fan
Favorite
Fantini, Lorenzo

IRST - Meldola
(P 144) EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA
Lorenzo Fantini
Favorite
Fan, Zheng-Fu

Beijing Cancer Hospital
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Zheng-Fu Fan
Favorite
Faria Andrade, Augusto

Research Institute McGill University Health Center
(P 69) H3.3G34W ONCOHISTONE IN OSTEOSARCOMA
Augusto Faria Andrade
Favorite
Farinatti, Sara

IRCCS Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Sara Farinatti
Favorite
Farinetti, Sara

IRCCS Humanitas Research Hospital
(P 290) ARTIFICIAL INTELLIGENCE-BASED COMPARISON OF ADULT AND ADOLESCENT AND YOUNG ADULTS (AYA) SARCOMAS: A PILOT STUDY
Sara Farinetti
Favorite
Farley, Lauren

Division of Surgical Oncology, Department of Surgery, University of California Davis
(P 230) HIGHER BODY MASS INDEX IS ASSOCIATED WITH DECREASED CIRCULATING AND INTRATUMORAL NATURAL KILLER CELLS IN SOFT TISSUE SARCOMA
Lauren Farley
Favorite
Farma, Jeffery

Fox Chase Cancer Center
(P 378) INGUINAL SARCOMAS - A RETROSPECTIVE ANALYSIS OF DIAGNOSIS, CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES (I-SARC): A STUDY BY TARPSWG
Jeffery Farma
Favorite
Farooqi, Ahsan

The University of Texas MD Anderson Cancer Center
(P 360) TREATMENT OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR WITH BROMODOMAIN EXTRA TERMINAL INHIBITOR (BETI) IN COMBINATION WITH RADIOTHERAPY
Ahsan Farooqi
Favorite
Faruqi, Ayra

Northwestern Medicine
(P 179) PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY
Ayra Faruqi
Favorite
Faruqi, Fahad

Northwestern Medicine
(P 179) PRIMARY MANAGEMENT OF LOCALIZED GASTROINTESTINAL STROMAL TUMORS WITH IMATINIB MONOTHERAPY: AN ALTERNATIVE TO RESECTION FOR PATIENTS PRECLUDED FROM SURGERY
Fahad Faruqi
Favorite
Fatehi, Amirreza

MedStar Georgetown Cancer Institute
(P 39) PATIENT OUTCOMES FOLLOWING MINIMALLY INVASIVE TREATMENT OF ANEURYSMAL BONE CYSTS USING DOXYCYCLINE
Amirreza Fatehi
Favorite
FATTORI, Antonin

University Hospitals of Strasbourg
(P 426) GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS
Antonin FATTORI
Favorite
Faulkner, Lisa

Clear Cell Sarcoma Foundation
(P 189) CLEAR CELL SARCOMA - REAL WORLD DATA ANALYSIS
Lisa Faulkner
Favorite
Fausti, Valentina

Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy
(P 144) EXPLORATORY ANALYSIS OF 68GA-FAPI-46 PET-CT IN SOFT TISSUE SARCOMA
Valentina Fausti
Favorite
Federico, Sara

St. Jude Children's Research Hospital
(P 288) ANGIOA: A SAFETY AND TOLERABILITY STUDY OF TRIPLE ANTI-ANGIOGENIC THERAPY COMBINED WITH PD-L1 BLOCKADE IN PEDIATRIC, ADOLESCENT AND YOUNG ADULT RECURRENT/REFRACTORY SOLID TUMORS
Sara Federico
Favorite
Federman, Noah

Departments of Pediatrics and Orthopaedic Surgery, David Geffen School of Medicine, University of California Los Angeles
(P 33) DESCRIPTIVE EVALUATION OF PATIENTS WITH DESMOID TUMOR AND CO-OCCURRING SOMATIC MUTATIONS OF CTNNB1 AND APC IN THE PHASE 3 DEFI TRIAL
Noah Federman
Favorite
Federman, Noah

UCLA David Geffen School of Medicine
(P 393) EFFICACY AND SAFETY OF LAROTRECTINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH TRK FUSION SARCOMAS
Noah Federman
Favorite
Feinberg, Tamar

Memorial Sloan Kettering Cancer Center
(P 338) PRECLINICAL EFFICACY OF DAN-222, A NOVEL POLYMERIC NANOPARTICLE, IN PEDIATRIC SOLID TUMOR MODELS
Tamar Feinberg
Favorite
Fei, Yuewei

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Yuewei Fei
Favorite
Felser, Brandi

Sarcoma Foundation of America
(P 206) PATIENT PERSPECTIVE ON LIPOSARCOMA DIAGNOSTIC JOURNEY: INTERIM PATIENT SURVEY RESULTS
Brandi Felser
Favorite
Femino, J. Dominic

Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California
(P 197) EVALUATION OF REVIEWS OF ORTHOPAEDIC ONCOLOGISTS ON INSTITUITIONAL AND PATIENT REVIEW WEBSITES
J. Dominic Femino
Favorite
Fenger, Joelle

Ethos Discovery
(P 115) PROSPECTIVE EVALUATION OF THORACOSCOPIC METASTASECTOMY IN DOGS: A NOVEL TRANSLATIONAL DRUG DEVELOPMENT PIPELINE TAGETING METASTATIC OSTEOSARCOMA
Joelle Fenger
Favorite
Feng, feifei

Zhengzhou University
(P 97) TRANSCRIPTOMICS REVEALS THAT OVEREXPRESSION OF LNCRNA HOTTIP REGULATES PKC PROTEIN ACTIVATION OF THE RAP1 SIGNALING PATHWAY FOR SYNOVIAL SARCOMA CELL PROGRESSION
feifei Feng
Favorite
Feng, Xiaolan

Tom Baker Cancer Center
(P 153) PATTERNS, MANAGEMENT AND SURVIVAL OUTCOMES OF PATIENTS WITH EPITHELIOID HEMANGIOENDOTHELIOMA: A NATIONWIDE ANALYSIS FROM THE CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION DATABASE
Xiaolan Feng
Favorite
Feng, Xiaolan

Tom Baker Cancer Centre
(P 174) INCIDENCE, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES FOR ADULT PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) IN ALBERTA, CANADA FROM 2008 - 2022.
Xiaolan Feng
Favorite
Feng, Xiaolan

Tom Baker Cancer Center
(P 176) LOSS OF PTEN EXPRESSION IN MINIGISTS AND CLINICALLY RELEVANT GISTS
Xiaolan Feng
Favorite
(P 293) CIC-REARRANGED SOFT TISSUE SARCOMAS: DOES CHEMOTHERAPY CHANGE NATURAL HISTORY AND PROGNOSIS? A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Xiaolan Feng
Favorite
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Xiaolan Feng
Favorite
(P 321) WHOLE ABDOMINAL RADIOTHERAPY IN CHILDREN AND YOUNG ADULTS WITH SARCOMA: A CANADIAN SARCOMA AND CLINICAL COLLABORATION (CANSARCC) STUDY
Xiaolan Feng
Favorite
Feng, Yi

Memorial Sloan Kettering Cancer Center
(P 302) HER2 PRETARGETED ALPHA PARTICLE RADIOIMMUNOTHERAPY FOR DESMOPLASTIC SMALL ROUND CELL TUMORS
Yi Feng
Favorite
Feng, Yi

Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
(P 416) TRIPLR COMNINATION THERAPY IN THE FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA WITH HIGH TUMOR BURDEN: INTERIM ANALYSIS FROM ALTER-S007 STUDY
Yi Feng
Favorite
Fennessy, Fiona

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Fiona Fennessy
Favorite
Ferguson, Michael

Division of Pediatric Hematology/Oncology, Riley Hospital for Children
(P 365) A SINGLE INSTITUTION COMPARISON OF OUTCOMES IN PEDIATRIC AND ADULT PATIENTS WITH GYNECOLOGIC ORIGIN RHABDOMYOSARCOMA
Michael Ferguson
Favorite
Ferguson, Peter

University of Toronto
(P 71) LIMB-SALVAGE SURGERY AFTER UNPLANNED SURGERY FOR EXTREMITY BONE SARCOMAS: 30-YEAR EXPERIENCE AT A TERTIARY REFERRAL CENTER
Peter Ferguson
Favorite
(P 238) INTRA-TUMORAL DC-LAMP EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN SOFT TISSUE SARCOMA
Peter Ferguson
Favorite
(P 281) THE UTILITY OF INTRAOPERATIVE MARROW MARGIN FROZEN SECTION IN EXTREMITY BONE SARCOMA RESECTION
Peter Ferguson
Favorite
(P 352) OUTCOMES OF PRIMARY INTRATHORACIC SOFT TISSUE SARCOMA
Peter Ferguson
Favorite
Fernandes, Italo

Hospital Israelita Albert Einstein
(P 242) MICROSATELLITE INSTABILITY AND CLINICAL USE IN SARCOMAS: A SYSTEMATIC REVIEW
Italo Fernandes
Favorite
Fernandes, Matheus

UERN
(P 232) IMMUNE CHECKPOINT INHIBITORS COMBINED WITH TYROSINE KINASE INHIBITORS FOR SOFT-TISSUE SARCOMAS: A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS
Matheus Fernandes
Favorite
Fernandes, Milena

Hospital Israelita Albert Einstein
(P 141) COMPREHENSIVE GENOMIC PROFILING OF PATIENTS DIAGNOSED WITH SARCOMA IN BRAZIL: MOLECULAR PROFILE AND ACTIONABILITY
Milena Fernandes
Favorite
Fernández, Elena

Hospital Clínico San Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Elena Fernández
Favorite
Ferraresi, Virginia

IRCCS Istituto Nazionale Tumori Regina Elena
(P 43) SAFETY AND EFFICACY WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED NO PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY
Virginia Ferraresi
Favorite
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Virginia Ferraresi
Favorite
(P 415) TRABECTEDIN PLUS OLAPARIB IN ADVANCED LEIOMYOSARCOMA PROGRESSING AFTER STANDARD TREATMENTS FOR ADVANCED DISEASE: A POOLED ANALYSIS OF TOMAS AND TOMAS2 STUDIES FROM THE ITALIAN SARCOMA GROUP.
Virginia Ferraresi
Favorite
Ferreira De Souza, Felipe

University of Miami Miller School of Medicine
(P 369) BLAND EMBOLIZATION AS ADJUNCT TREATMENT FOR HEPATIC EPITHELIOID HEMANGIOENDOTHELIOMA
Felipe Ferreira De Souza
Favorite
Ferrena, Alexander

Albert Einstein College of Medicine
(P 59) COMPREHENSIVE SINGLE CELL TRANSCRIPTOMICS ANALYSIS OF MURINE OSTEOSARCOMA UNCOVERS SKP2 FUNCTION IN METASTASIS, GENOMIC INSTABILITY AND IMMUNE ACTIVATION AND REALS ADDITIONAL TARGET PATHWAYS
Alexander Ferrena
Favorite
Ferrero, Giulio

Department of Clinical and Biological Sciences, University of Turin
(P 345) TRANSCRIPTOMIC AND PHENOTYPIC CHARACTERIZATION OF AN IMMUNOCOMPETENT LEIOMYOSARCOMA MOUSE MODEL.
Giulio Ferrero
Favorite
Ferrillo, Giuseppe

IRCCS Humanitas Research Hospital
(P 124) ASSESSMENT OF THE MECHANISMS OF ACTION OF ERIBULIN IN PATIENTS WITH ADVANCED LIPOSARCOMA THROUGH THE EVALUATION OF THE RADIOLOGICAL, FUNCTIONAL AND TISSUE RESPONSE: A MONOCENTRIC PROSPECTIVE STUDY
Giuseppe Ferrillo
Favorite
Fetting, Nikki

Washington University in St. Louis School of Medicine
(P 145) EXPLORING L-TYPE AMINO ACID TRANSPORTER 1 (LAT1) AS A DIAGNOSTIC MARKER AND THERAPEUTIC TARGET IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (MPNST)
Nikki Fetting
Favorite
Fetzer, Erin

The Ohio State University
(P 244) PREDICTIVE VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN IMMUNOTHERAPY OUTCOMES IN ADVANCED SARCOMA
Erin Fetzer
Favorite
(P 328) DETERMINING BIOMARKERS FOR GEMCITABINE RESPONSE IN SOFT TISSUE SARCOMAS: LESSONS LEARNED FROM PANCREATIC CANCER
Erin Fetzer
Favorite
Fetzko, Stephanie

Baylor College of Medicine
(P 315) SALVAGE THERAPY EFFICACY IS MODIFIED BY RISK GROUP AT DIAGNOSIS IN PATIENTS WITH RELAPSED RHABDOMYOSARCOMA
Stephanie Fetzko
Favorite
Fierstein, Jamie

Epidemiology and Biostatistics Shared Resource, Johns Hopkins All Children's Institute for Clinical and Translational Research, Johns Hopkins All Children's Hospital
(P 316) SECONDARY RHABDOMYOSARCOMA IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS
Jamie Fierstein
Favorite
Finkbeiner, Melanie

Alberta Children's Hospital
(P 320) WHAT IS THE ROLE OF CHEMOTHERAPY IN PATIENTS (PTS) WITH SPINDLE CELL/SCLEROSING RHABDOMYOSARCOMA (SCRMS): A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
Melanie Finkbeiner
Favorite
Finlay, Darren

National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute
(P 27) SUMO2 INHIBITION REVERSES ABERRANT EPIGENETIC REWIRING DRIVEN BY SYNOVIAL SARCOMA FUSION ONCOPROTEINS AND IMPAIRS SARCOMAGENESIS
Darren Finlay
Favorite
Finnegan, Maureen

Roswell Park Comprehensive Cancer Center
(P 35) EARLY REAL WORLD EXPERIENCE WITH NIROGACESTAT IN PATIENTS WITH DESMOID FIBROMATOSIS
Maureen Finnegan
Favorite
Fiocco, Marta

Leiden University Medical Center
(P 194) EFFECTIVENESS OF A RISK PREDICTION TOOL (PERSARC) ON THE QUALITY OF TREATMENT DECISIONS IN SOFT-TISSUE SARCOMA PATIENTS (VALUE-PERSARC TRIAL)
Marta Fiocco
Favorite
(P 274) PROXIMAL HUMERAL ENDOPROSTHETIC RECONSTRUCTION: RESULTS FROM THE MUTARS ORTHOPEDIC REGISTRY EUROPE (MORE)
Marta Fiocco
Favorite
(P 349) LONG-TERM SURVIVAL OF PARTICIPANTS IN THE PASART-1 AND PASART-2 TRIALS OF NEO-ADJUVANT PAZOPANIB AND RADIOTHERAPY IN SOFT TISSUE SARCOMA
Marta Fiocco
Favorite
Fiore, Marco

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Marco Fiore
Favorite
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Marco Fiore
Favorite
(P 213) REGIONAL KNOWLEDGE TRANSLATION IN RETROPERITONEAL SARCOMAS: IMPACT OF AN EDUCATIONAL WEBINAR SERIES BY THE MEXICAN SARCOMA GROUP
Marco Fiore
Favorite
(P 376) IMPACT OF SITE OF ORIGIN ON THE PROGNOSIS OF PATIENTS WITH PRIMARY RESECTABLE NON-UTERINE ABDOMINAL LEIOMYOSARCOMA
Marco Fiore
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Marco Fiore
Favorite
Firmin, Nelly

ICM, Institut du Cancer de Montpellier
(P 125) CHARACTERISTICS, MANAGEMENT AND SURVIVAL OF N=7314 LIPOSARCOMAS FROM THE NATIONWIDE NETSARC REGISTRY IN FRANCE SINCE 2010
Nelly Firmin
Favorite
Fischerova, Daniela

Charles University and General University Hospital in Prague, Prague
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Daniela Fischerova
Favorite
Fisher, Lauren

Dana-Farber Cancer Institute
(P 195) ENHANCING PARTICIPANT ENGAGEMENT IN A NOVEL PATIENT-PARTNERED CANCER GENOMICS RESEARCH EFFORT FOR RARE AND AGGRESSIVE SARCOMAS
Lauren Fisher
Favorite
Flacher, Vincent

UPR3572 CNRS Laboratory Institute of Molecular and Cellular Biology
(P 75) METABOLIC EVALUATION OF THE RELATIONSHIP BETWEEN MACROPHAGES AND OSTEOSARCOMA TUMOR CELLS
Vincent Flacher
Favorite
Fletcher, Christopher

Brigham & Women's Hospital and Harvard Medical School
(P 110) INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY OF PLEOMORPHIC RHABDOMYOSARCOMA (P-RMS), A PUSH PLATFORM STUDY: OUTCOME OF LOCALIZED AND ADVANCED DISEASE
Christopher Fletcher
Favorite
FLETCHER, Jonathan

Harvard Medical School
(P 19) INVOLVEMENT OF O-GLCNAC TRANSFERASE IN RESISTANCE TO DOXORUBICIN AND CELL DEATH IN PRECLINICAL MODELS OF LEIOMYOSARCOMA AND DESMOID TUMORS
Jonathan FLETCHER
Favorite
(P 412) SARC044: A PHASE II TRIAL OF BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GIST WHO PROGRESSED ON SUNITINIB MONOTHERAPY
Jonathan FLETCHER
Favorite
Fleuren, Emmy

Children's Cancer Institute
(P 299) EXPLORING THE POTENTIAL OF PHOSPHOPROTEOMIC PROFILING FOR TARGET DISCOVERY IN HIGH-RISK OSTEOSARCOMA: A PATHWAY TO NOVEL THERAPIES?
Emmy Fleuren
Favorite
Fling, Steven

Fred Hutchinson Cancer Center
(P 222) ANALYSIS OF THE CITN-13 SARCOMA ARM: PEMBROLIZUMAB AND INTERFERON GAMMA FOR SYNOVIAL SARCOMA AND MYXOID/ ROUND CELL LIPOSARCOMA
Steven Fling
Favorite
Florio, Michela

Ospedale Pediatrico Bambino Gesù
(P 311) QUANTIFICATION OF TUMOUR-INFILTRATING IMMUNE CELLS THROUGH DECONVOLUTION OF DNA METHYLATION DATA IN EWING SARCOMAS
Michela Florio
Favorite
Florou, Vaia

University of Utah
(P 246) THE GENOMIC AND IMMUNE LANDSCAPE OF LIPOSARCOMA AND ITS SUBTYPES
Vaia Florou
Favorite
Foijer, Floris

University Medical Centre Groningen
(P 03) CDK4 IS CO-AMPLIFIED WITH EITHER TP53 PROMOTER GENE FUSIONS OR MDM2 THROUGH DISTINCT MECHANISMS IN OSTEOSARCOMA
Floris Foijer
Favorite
Foppolo, Sophie

UMR CNRS 7021, university of Strasbourg
(P 426) GD2 HETEROGENEIC EXPRESSION IN OSTEOSARCOMAS AND EWING SARCOMAS UNDERLYING A WORST PROGNOSIS
Sophie Foppolo
Favorite
Forbes, Thomas

National Institute of Health
(P 47) A PHASE 2 STUDY OF OLAPARIB IN METASTATIC IDH1 AND IDH2 MUTANT CHONDROSARCOMAS
Thomas Forbes
Favorite
Fordham, Ashleigh

Children's Cancer Institute
(P 299) EXPLORING THE POTENTIAL OF PHOSPHOPROTEOMIC PROFILING FOR TARGET DISCOVERY IN HIGH-RISK OSTEOSARCOMA: A PATHWAY TO NOVEL THERAPIES?
Ashleigh Fordham
Favorite
Ford, Samuel

Queen Elizabeth Hospital
(P 383) PRE-OPERATIVE SPLIT RENAL FUNCTION RADIONUCLIDE IMAGING IN SURGICAL PLANNING FOR MULTI-VISCERAL RESECTION OF RETROPERITONEAL SARCOMA: A RETROSPECTIVE COHORT STUDY
Samuel Ford
Favorite
(P 390) VARIATIONS IN GLOBAL PATTERNS OF CARE FOR RETROPERITONEAL SARCOMAS - A STUDY BY TARPSWG
Samuel Ford
Favorite
Foster, Jared

NCI CTEP
(P 413) SUSTAINED EFFICACY DURING DRUG HOLIDAY ON ATEZOLIZUMAB IN PATIENTS WITH ALVEOLAR SOFT PART SARCOMA (ASPS)
Jared Foster
Favorite
Fourman, Mitchell

Montefiore Medical Center
(P 284) WOUND VAC TEMPORIZATION AFTER TUMOR RESECTION OF SOFT TISSUE SARCOMAS - A COST ANALYSIS IN A PROPENSITY-SCORE MATCHED POPULATION
Mitchell Fourman
Favorite
Fox, Amanda

University of Michigan
(P 45) UTILIZATION OF MENTAL HEALTH AND SUPPORTIVE CARE RESOURCES AMONG PATIENTS WITH DESMOID TUMORS
Amanda Fox
Favorite
(P 308) PALLIATIVE CARE INVOLVEMENT FOR ADOLESCENTS AND YOUNG ADULTS WITH BONE AND SOFT TISSUE SARCOMAS
Amanda Fox
Favorite
Fraile, Carlos

Hospital Clinico San Carlos
(P 208) PSYCOLOGICAL ASSESSMENT IN A SAMPLE OF PATIENTS AT HOSPITAL CLÍNICO SAN CARLOS (MADRID), SARCOMA NATIONAL REFERRAL CENTRE IN SPAIN. HIGHLIGTHING THE NEED OF A GLOBAL STANDARIZED PSYCHOLOGICAL APPROACH
Carlos Fraile
Favorite
Franchi, Alessandro

University of Pisa,
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Alessandro Franchi
Favorite
Franchini, Melania

Columbia University Irving Medical Center
(P 418) A SYSTEMS BIOLOGY APPROACH FOR CHARACTERIZING TUMOR HETEROGENEITY AND CELL STATE-SPECIFIC THERAPEUTIC VULNERABILITIES FROM SINGLE NUCLEUS RNA-SEQ PROFILING OF DESMOPLASTIC SMALL ROUND CELL TUMORS
Melania Franchini
Favorite
Franza, Andrea

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Andrea Franza
Favorite
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Andrea Franza
Favorite
Fraser, Luke

The University of Kansas Medical Center
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Luke Fraser
Favorite
Freed, Daniel

Chordoma Foundation
(P 02) A PRECLINICAL ASSAY PIPELINE TO IDENTIFY AND OPTIMIZE BRACHYURY-TARGETED THERAPIES IN CHORDOMA AND OTHER SOLID TUMORS
Daniel Freed
Favorite
(P 425) EXPLORING MECHANISMS OF EGFR INHIBITOR RESISTANCE IN CHORDOMA
Daniel Freed
Favorite
Freeland, Jack

University of California Los Angeles
(P 08) ELUCIDATING THE ROLE OF YAP IN SARCOMA DEVELOPMENT
Jack Freeland
Favorite
Frega, Giorgio

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy
(P 77) MULTI-PARAMETRICAL PROFILING OF CHONDROSARCOMA
Giorgio Frega
Favorite
(P 86) RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL
Giorgio Frega
Favorite
Frey, Alexandre

Yale University
(P 98) A MULTIEPITOPE MRNA VACCINE FOR KAPOSI SARCOMA: AN IMMUNOINFORMATIC APPROACH
Alexandre Frey
Favorite
Friedlander, Michael

Prince of Wales Hospital
(P 372) ESGO, EURACAN AND GCIG UTERINE SARCOMA GUDLINES: THE FIRST GLOBAL CONSENSUS
Michael Friedlander
Favorite
Friedman, Debra

Vanderbilt University Medical Center
(P 199) FINANCIAL TOXICITY AMONG SARCOMA PATIENTS AND ASSOCIATED FACTORS
Debra Friedman
Favorite
(P 297) ESTABLISHING A PEDIATRIC, ADOLESCENT AND YOUNG ADULT COHORT OF SARCOMA PATIENTS TO STUDY ONCOLOGIC AND NON-ONCOLOGIC OUTCOMES
Debra Friedman
Favorite
Friedman, Elizabeth

University of Kansas
(P 36) EARLY REAL-WORLD EXPERIENCE WITH THE USE OF NIROGACESTAT FOR THE TREATMENT OF DESMOID FIBROMATOSIS
Elizabeth Friedman
Favorite
Fritchie, Karen

Cleveland Clinic
(P 152) NOVEL PAX3::MAML3 FUSION IDENTIFIED IN ALVEOLAR RHABDOMYOSARCOMA: USING DNA METHYLATION TO EXPANDE THE GENETIC SPECTRUM OF "FUSION POSITIVE" CASES
Karen Fritchie
Favorite
Fuchs, Bruno

Swiss Sarcoma Network
(P 184) A SYSTEMATIC REVIEW ABOUT CLINICAL PROGNOSTIC MODELS FOR SARCOMAS
Bruno Fuchs
Favorite
(P 204) IMPACT OF UNPéLANNED EXCISION ON THE SURVIVAL OF SARCOMA PATIENTS - A TARGET TRIAL EMULATION
Bruno Fuchs
Favorite
Fujii, Hiromasa

Nara Medical University
(P 85) PTEROSTILBENE SENSITIZES OSTEOSARCOMA CELLS TO KILLING BY C-MYC INHIBITORS
Hiromasa Fujii
Favorite
(P 313) RELATION BETWEEN NUTRITIONAL/INFLAMMATORY PARAMETERS AND PROGNOSIS IN CHILDHOOD SARCOMA PATIENTS
Hiromasa Fujii
Favorite
Fujimoto, Hiroyuki

Department of Urology, National Cancer Center Hospital, Tokyo, Japan
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Hiroyuki Fujimoto
Favorite
Fujisawa, Takeshi

National Cancer Center Hospital East
(P 354) PROTON BEAM THERAPY FOR PEDIATRIC AND ADOLESCENT SARCOMA FROM OVERSEAS
Takeshi Fujisawa
Favorite
Fujito, Takeo

Nagoya university hospital
(P 280) SURGICAL OUTCOMES OF PELVIC CHONDROSARCOMA WITH A FOCUS ON WALKING ABILITY
Takeo Fujito
Favorite
Fujiwara, Toshifumi

Kyushu University
(P 203) IMPACT OF COVID-19 PANDEMIC ON BONE AND SOFT TISSUE SARCOMA PATIENTS' CONSULTATION AND DIAGNOSIS
Toshifumi Fujiwara
Favorite
Fukushima, Suguru

National Cancer Center Hospital
(P 134) REAL-WORLD CLINICAL OUTCOME OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL DEDIFFERENTIATED LIPOSARCOMA
Suguru Fukushima
Favorite
(P 220) SPORTS ACTIVITIES IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT SURVIVORS OF MALIGNANT BONE SARCOMAS
Suguru Fukushima
Favorite
Fumagalli, Elena

Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano
(P 160) UTERINE PECOMA: REPORT OF MOLECULAR AND CLINICAL FEATURES IN A SERIES OF PATIENTS TREATED AT A REFERRAL INSTITUTION
Elena Fumagalli
Favorite
Fumagalli, Elena

Istituto Nazionale Tumori
(P 171) GASTROINTESTINAL STROMAL TUMOURS (GISTS) IN NEUROFIBROMATOSIS TYPE (NF1): A SINGLE-CENTER OBSERVATIONAL RETROSPECTIVE STUDY
Elena Fumagalli
Favorite
Fumagalli, Elena

Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano
(P 368) AGGRESSIVE PERINEAL ANGIOMYXOMA UNDERGOING SYSTEMIC TREATMENT: AN UPDATED REPORT OF 8-YEARS' EXPERIENCE IN A REFERRAL CENTER
Elena Fumagalli
Favorite
Futreal, P Andrew

MD Anderson Cancer Center
(P 233) IMMUNE CLASSES OF LEIOMYOSARCOMA DRIVEN BY B CELL INFILTRATE AND CTLA4 EXPRESSION
P Andrew Futreal
Favorite
(P 398) PREDICTORS OF EFFICACY IN PATIENTS WITH SOFT TISSUE SARCOMAS TREATED WITH PAZOPANIB
P Andrew Futreal
Favorite
Fu, Xiao-Hong

RWE, Boehringer Ingelheim, Shanghai, China
(P 132) PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND DISEASE BURDEN OF DEDIFFERENTIATED LIPOSARCOMA IN CHINA: A REAL-WORLD STUDY BASED ON NATIONAL CANCER REGISTRY
Xiao-Hong Fu
Favorite